Partnering to support the next generation of epilepsy researchers

Penny A. Dacks; Sonya B. Dumanis; Brandy Fureman; Steven L. Roberds; Kari L. Rosbeck; Jay Etta Hecker; Jacqueline A. French; Aristea S. Galanopoulou; Cynthia Harden

doi:10.1016/j.yebeh.2017.07.034

Partnering to support the next generation of epilepsy researchers

Penny A. Dacks, Sonya B. Dumanis, Brandy Fureman, Steven L. Roberds, Kari L. Rosbeck, Jay Etta Hecker, Jacqueline A. French, Aristea S. Galanopoulou, Cynthia Harden

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	258-260
Number of pages	3
Journal	Epilepsy and Behavior
Volume	75
DOIs	https://doi.org/10.1016/j.yebeh.2017.07.034
State	Published - Oct 2017
Externally published	Yes

Access to Document

10.1016/j.yebeh.2017.07.034

Cite this

@article{582938f2262f4986ad07d3499d281a7b,

title = "Partnering to support the next generation of epilepsy researchers",

author = "Dacks, {Penny A.} and Dumanis, {Sonya B.} and Brandy Fureman and Roberds, {Steven L.} and Rosbeck, {Kari L.} and Hecker, {Jay Etta} and French, {Jacqueline A.} and Galanopoulou, {Aristea S.} and Cynthia Harden",

note = "Funding Information: ASG, PAD, & JH declare no COI in regard to the content of this manuscript. SLB & KLR are employed by the TS Alliance, which receives research funding from Novartis. No funds from Novartis were used to support the grants discussed in this editorial. CH receives royalties from Up-to-Date and Wiley. JAF receives NYU salary support from the Epilepsy Foundation and for consulting work on behalf of the Epilepsy Study Consortium for Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cerecor, Concert Pharmaceuticals, Engage, Eisai, Glaxo Smith-Kline, GW Pharma, Marinus, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Otzuka, Ovid, Sage Therapeutics, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix, and Zynerba. J. French has also received research grants from Acorda, Alexza, Eisai Medical Research, LCGH, Lundbeck, Pfizer, SK Life Sciences, Sunovion, Takeda, and UCB, as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, Epilepsy Therapy Project, and NINDS. She is on the Scientific Advisory Board of Ovid, Sage Therapeutics, and Blackfynn. She is on the editorial board of Lancet Neurology, Neurology Today, and Epileptic disorders. She is a scientific officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Eisai, GW Pharma, Marinus, Nestle Life Sciences, Pfizer, Sage, SK life Sciences, Takeda, UCB, Upsher-Smith, Zogenix, and Zynerba. ",

year = "2017",

month = oct,

doi = "10.1016/j.yebeh.2017.07.034",

language = "English",

volume = "75",

pages = "258--260",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Partnering to support the next generation of epilepsy researchers

AU - Dacks, Penny A.

AU - Dumanis, Sonya B.

AU - Fureman, Brandy

AU - Roberds, Steven L.

AU - Rosbeck, Kari L.

AU - Hecker, Jay Etta

AU - French, Jacqueline A.

AU - Galanopoulou, Aristea S.

AU - Harden, Cynthia

N1 - Funding Information: ASG, PAD, & JH declare no COI in regard to the content of this manuscript. SLB & KLR are employed by the TS Alliance, which receives research funding from Novartis. No funds from Novartis were used to support the grants discussed in this editorial. CH receives royalties from Up-to-Date and Wiley. JAF receives NYU salary support from the Epilepsy Foundation and for consulting work on behalf of the Epilepsy Study Consortium for Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cerecor, Concert Pharmaceuticals, Engage, Eisai, Glaxo Smith-Kline, GW Pharma, Marinus, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Otzuka, Ovid, Sage Therapeutics, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix, and Zynerba. J. French has also received research grants from Acorda, Alexza, Eisai Medical Research, LCGH, Lundbeck, Pfizer, SK Life Sciences, Sunovion, Takeda, and UCB, as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, Epilepsy Therapy Project, and NINDS. She is on the Scientific Advisory Board of Ovid, Sage Therapeutics, and Blackfynn. She is on the editorial board of Lancet Neurology, Neurology Today, and Epileptic disorders. She is a scientific officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Eisai, GW Pharma, Marinus, Nestle Life Sciences, Pfizer, Sage, SK life Sciences, Takeda, UCB, Upsher-Smith, Zogenix, and Zynerba.

PY - 2017/10

Y1 - 2017/10

UR - http://www.scopus.com/inward/record.url?scp=85028342687&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2017.07.034

DO - 10.1016/j.yebeh.2017.07.034

M3 - Editorial

C2 - 28843951

AN - SCOPUS:85028342687

SN - 1525-5050

VL - 75

SP - 258

EP - 260

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

ER -